Review



bv650 anti mouse cx3cr1  (Revvity Signals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Revvity Signals bv650 anti mouse cx3cr1
    (A) Schematic of tumor challenges in mice immunized with OVA/ poly(I:C). (B) The growth of B16-OVA tumors after tumor injection on day 7 after immunization. ( C ) The growth of B16-OVA (left flank) or B16F10 (top right flank) tumors injected on day 45 in mice that rejected the first tumor challenge at lower right flank on day 7 as in ( B ). The growth of B16-OVA or B16F10 tumors in naïve mice was used as control. (D) The growth of B16-OVA tumors after tumor injection on day 21 after immunization. ( E - G ) Frequency of CD44+CD62L+( E ), <t>CX3CR1+(</t> F ), CD107a degranulation ( G ) in splenic CD11a high CD8+ T cells from the baseline and weeks after immunization. CD11a was used to identify antigen-primed T cells. ( H-J ) the tumor growth ( H-I ) and survival ( J ) of mice with B16-OVA tumors after treatment with anti-PD-L1 (10B5) starting at day 7 after tumor injection for a total of five doses.
    Bv650 Anti Mouse Cx3cr1, supplied by Revvity Signals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bv650 anti mouse cx3cr1/product/Revvity Signals
    Average 86 stars, based on 1 article reviews
    bv650 anti mouse cx3cr1 - by Bioz Stars, 2025-03
    86/100 stars

    Images

    1) Product Images from "PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity"

    Article Title: PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity

    Journal: bioRxiv

    doi: 10.1101/2025.01.18.631253

    (A) Schematic of tumor challenges in mice immunized with OVA/ poly(I:C). (B) The growth of B16-OVA tumors after tumor injection on day 7 after immunization. ( C ) The growth of B16-OVA (left flank) or B16F10 (top right flank) tumors injected on day 45 in mice that rejected the first tumor challenge at lower right flank on day 7 as in ( B ). The growth of B16-OVA or B16F10 tumors in naïve mice was used as control. (D) The growth of B16-OVA tumors after tumor injection on day 21 after immunization. ( E - G ) Frequency of CD44+CD62L+( E ), CX3CR1+( F ), CD107a degranulation ( G ) in splenic CD11a high CD8+ T cells from the baseline and weeks after immunization. CD11a was used to identify antigen-primed T cells. ( H-J ) the tumor growth ( H-I ) and survival ( J ) of mice with B16-OVA tumors after treatment with anti-PD-L1 (10B5) starting at day 7 after tumor injection for a total of five doses.
    Figure Legend Snippet: (A) Schematic of tumor challenges in mice immunized with OVA/ poly(I:C). (B) The growth of B16-OVA tumors after tumor injection on day 7 after immunization. ( C ) The growth of B16-OVA (left flank) or B16F10 (top right flank) tumors injected on day 45 in mice that rejected the first tumor challenge at lower right flank on day 7 as in ( B ). The growth of B16-OVA or B16F10 tumors in naïve mice was used as control. (D) The growth of B16-OVA tumors after tumor injection on day 21 after immunization. ( E - G ) Frequency of CD44+CD62L+( E ), CX3CR1+( F ), CD107a degranulation ( G ) in splenic CD11a high CD8+ T cells from the baseline and weeks after immunization. CD11a was used to identify antigen-primed T cells. ( H-J ) the tumor growth ( H-I ) and survival ( J ) of mice with B16-OVA tumors after treatment with anti-PD-L1 (10B5) starting at day 7 after tumor injection for a total of five doses.

    Techniques Used: Injection, Control



    Similar Products

    bv650 anti mouse cx3cr1  (Revvity Signals)
    86
    Revvity Signals bv650 anti mouse cx3cr1
    (A) Schematic of tumor challenges in mice immunized with OVA/ poly(I:C). (B) The growth of B16-OVA tumors after tumor injection on day 7 after immunization. ( C ) The growth of B16-OVA (left flank) or B16F10 (top right flank) tumors injected on day 45 in mice that rejected the first tumor challenge at lower right flank on day 7 as in ( B ). The growth of B16-OVA or B16F10 tumors in naïve mice was used as control. (D) The growth of B16-OVA tumors after tumor injection on day 21 after immunization. ( E - G ) Frequency of CD44+CD62L+( E ), <t>CX3CR1+(</t> F ), CD107a degranulation ( G ) in splenic CD11a high CD8+ T cells from the baseline and weeks after immunization. CD11a was used to identify antigen-primed T cells. ( H-J ) the tumor growth ( H-I ) and survival ( J ) of mice with B16-OVA tumors after treatment with anti-PD-L1 (10B5) starting at day 7 after tumor injection for a total of five doses.
    Bv650 Anti Mouse Cx3cr1, supplied by Revvity Signals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bv650 anti mouse cx3cr1/product/Revvity Signals
    Average 86 stars, based on 1 article reviews
    bv650 anti mouse cx3cr1 - by Bioz Stars, 2025-03
    86/100 stars
    		  Buy from Supplier
    bv650 anti mouse cx3cr1 biolegend  (Revvity Signals)
    86
    Revvity Signals bv650 anti mouse cx3cr1 biolegend
    (A) Schematic of tumor challenges in mice immunized with OVA/ poly(I:C). (B) The growth of B16-OVA tumors after tumor injection on day 7 after immunization. ( C ) The growth of B16-OVA (left flank) or B16F10 (top right flank) tumors injected on day 45 in mice that rejected the first tumor challenge at lower right flank on day 7 as in ( B ). The growth of B16-OVA or B16F10 tumors in naïve mice was used as control. (D) The growth of B16-OVA tumors after tumor injection on day 21 after immunization. ( E - G ) Frequency of CD44+CD62L+( E ), <t>CX3CR1+(</t> F ), CD107a degranulation ( G ) in splenic CD11a high CD8+ T cells from the baseline and weeks after immunization. CD11a was used to identify antigen-primed T cells. ( H-J ) the tumor growth ( H-I ) and survival ( J ) of mice with B16-OVA tumors after treatment with anti-PD-L1 (10B5) starting at day 7 after tumor injection for a total of five doses.
    Bv650 Anti Mouse Cx3cr1 Biolegend, supplied by Revvity Signals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bv650 anti mouse cx3cr1 biolegend/product/Revvity Signals
    Average 86 stars, based on 1 article reviews
    bv650 anti mouse cx3cr1 biolegend - by Bioz Stars, 2025-03
    86/100 stars
    		  Buy from Supplier
    bv650 anti mouse cx3cr1  (Thermo Fisher)
    86
    Thermo Fisher bv650 anti mouse cx3cr1
    (A) Schematic of tumor challenges in mice immunized with OVA/ poly(I:C). (B) The growth of B16-OVA tumors after tumor injection on day 7 after immunization. ( C ) The growth of B16-OVA (left flank) or B16F10 (top right flank) tumors injected on day 45 in mice that rejected the first tumor challenge at lower right flank on day 7 as in ( B ). The growth of B16-OVA or B16F10 tumors in naïve mice was used as control. (D) The growth of B16-OVA tumors after tumor injection on day 21 after immunization. ( E - G ) Frequency of CD44+CD62L+( E ), <t>CX3CR1+(</t> F ), CD107a degranulation ( G ) in splenic CD11a high CD8+ T cells from the baseline and weeks after immunization. CD11a was used to identify antigen-primed T cells. ( H-J ) the tumor growth ( H-I ) and survival ( J ) of mice with B16-OVA tumors after treatment with anti-PD-L1 (10B5) starting at day 7 after tumor injection for a total of five doses.
    Bv650 Anti Mouse Cx3cr1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bv650 anti mouse cx3cr1/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    bv650 anti mouse cx3cr1 - by Bioz Stars, 2025-03
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Schematic of tumor challenges in mice immunized with OVA/ poly(I:C). (B) The growth of B16-OVA tumors after tumor injection on day 7 after immunization. ( C ) The growth of B16-OVA (left flank) or B16F10 (top right flank) tumors injected on day 45 in mice that rejected the first tumor challenge at lower right flank on day 7 as in ( B ). The growth of B16-OVA or B16F10 tumors in naïve mice was used as control. (D) The growth of B16-OVA tumors after tumor injection on day 21 after immunization. ( E - G ) Frequency of CD44+CD62L+( E ), CX3CR1+( F ), CD107a degranulation ( G ) in splenic CD11a high CD8+ T cells from the baseline and weeks after immunization. CD11a was used to identify antigen-primed T cells. ( H-J ) the tumor growth ( H-I ) and survival ( J ) of mice with B16-OVA tumors after treatment with anti-PD-L1 (10B5) starting at day 7 after tumor injection for a total of five doses.

    Journal: bioRxiv

    Article Title: PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity

    doi: 10.1101/2025.01.18.631253

    Figure Lengend Snippet: (A) Schematic of tumor challenges in mice immunized with OVA/ poly(I:C). (B) The growth of B16-OVA tumors after tumor injection on day 7 after immunization. ( C ) The growth of B16-OVA (left flank) or B16F10 (top right flank) tumors injected on day 45 in mice that rejected the first tumor challenge at lower right flank on day 7 as in ( B ). The growth of B16-OVA or B16F10 tumors in naïve mice was used as control. (D) The growth of B16-OVA tumors after tumor injection on day 21 after immunization. ( E - G ) Frequency of CD44+CD62L+( E ), CX3CR1+( F ), CD107a degranulation ( G ) in splenic CD11a high CD8+ T cells from the baseline and weeks after immunization. CD11a was used to identify antigen-primed T cells. ( H-J ) the tumor growth ( H-I ) and survival ( J ) of mice with B16-OVA tumors after treatment with anti-PD-L1 (10B5) starting at day 7 after tumor injection for a total of five doses.

    Article Snippet: After that, cells were stained with cell surface mouse antibodies based on the needs of experiments including PerCP/Cyanine5.5 anti-mouse TCRβ chain Antibody (Biolegend, Cat#109227, Clone H57-597), BUV395 Rat Anti-Mouse CD4 (BD Biosciences, Cat#563790, clone GK1.5), BUV496 Rat Anti-Mouse CD8a (BD Biosciences, Cat#569181, Clone 53-6.7), Brilliant Ultra Violet™ 563 CD25 monoclonal antibody (Thermofisher, Cat# 365-0251-82, Clone PC61.5), BUV615 Rat Anti-Mouse CD24 (BD biosciences, Cat#751499, Clone M1/69), BV711 Rat Anti-Mouse CD11a (BD biosciences, Cat#740676, Clone M1/4), BV570 anti-mouse CD44 Antibody (Biolegend, Cat#103037, Clone IM7), PE/Cy7 anti-mouse CD62L Antibody (Biolegend, Cat#104418, Clone, MEL-14), APC/Cy7 anti-mouse PD-1 Antibody (Biolegend, Cat#135224, Clone 29F.1A12), BV785 anti-mouse antibody (Biolegend, Cat#104543, Clone H1.2F3), BV750 Rat Anti-Mouse CD117 (BD Biosciences, Cat#747412, Clone 2B8), BV650 anti-mouse CX3CR1 (Biolegend, Cat#149033, Clone SA011F11), BUV737 Rat Anti-Mouse CD127 (BD Biosciences, Cat#612841, Clone SB/199), PE/Fire 810 anti-mouse Tim-3 (Biolegend, Cat#149033, Clone RMT3-23) resuspended in the FACS buffer (PBS + 2% FBS + 2mM EDTA).

    Techniques: Injection, Control